Introduction
Vitamin K epoxide reductase (VKOR) enzyme converts vitamin K (VK) 2, 3-epoxide to VK hydroquinone, a required cofactor for the post-translational gamma-carboxylation of several blood coagulation factors (factors II, VII, IX, X, Protein C and S) and other VK-dependent proteins, such as osteocalcin bone Gla protein and matrix Gla protein. [1] [2] [3] The gamma-glutamyl carboxylase enzyme requires reduced VK as a cofactor in the clotting pathway. Oral anticoagulants (OAs) (warfarin, acenocoumarol and phenprocoumon) inhibit the regeneration of reduced VK by targeting the enzyme VKOR and there by blocks the clotting mechanism. [1, 4] The inter-individual variability in OA dose is influenced by the genes of two BACKGROUND: Genetic variation in the vitamin K epoxide reductase complex (VKORC1) and cytochrome P450 4F2 (CYP4F2) genes were found to be strongly associated with the oral anticoagulant (OA) dose requirement. The distribution of genetic variation in these two genes was found to show large inter-and intra-ethnic difference. MATERIALS AND METHODS: A total of 470 unrelated, healthy volunteers of South Indians of either sex (age: 18-60 years) were enrolled for the study. A 5 ml of venous blood was collected and the genomic deoxyribonucleic acid (DNA) was extracted by using phenol-chloroform extraction method. Real-time quantitative polymerase chain reaction (RT-PCR) method was used for genotyping.
RESULTS:
The variant allele frequencies of VKORC1 rs2359612 (T), rs8050894 (C), rs9934438 (T) and rs9923231 (A) were found to be 11.0%, 11.8%, 11.7% and 12.0%, respectively. The variant allele VKORC1 rs7294 was (80.1%) more frequent and the variant allele CYP4F2 * 3 was found to be 41.8% in South Indians. The allele, genotype and haplotype frequencies of VKORC1 and CYP4F2 gene were distinct from other compared HapMap populations (P < 0.0001). CONCLUSION: The findings of our study provide the basic genetic information for further pharmacogenetic based investigation of OA therapy in the population. enzyme activity and affects the pharmacokinetics of OA and its dose requirement. The variants in the VKORC1 gene influence the pharmacodynamics response to
OAs. [5] [6] [7] Polymorphisms in the VKORC1 gene encoding the VKOR enzyme leads to inter individual variability in susceptibility to develop bleeding and other adverse reactions to oral anti-coagulants. [8, 9] The impact of VKORC1 genetic variation on warfarin dose requirement confirmed that the genetic polymorphisms of VKORC1 are significant determinants of inter-individual dose requirement. It has been found that genetic variations in the CYP2C9 and VKORC1 genes together account for 35-50% variability in the dose requirement for initiation and maintenance of OAs. [5, 10, 11] There is an evidence that specific haplotypes can help to determine the dose of [12] CYP4F2 genetic polymorphism (rs2108622) was found to be associated with reduced hepatic CYP4F2 enzyme activity and higher levels of VK. The presence of this variant allele is associated with a higher warfarin dose requirement. [13] [14] [15] Reich et al. [17] found that the ancestral South Indians were distinct from the ancestral North Indians and East Indians.
In our previous studies, we have found that the polymorphic profile of the genes encoding some of the Phase I and Phase II drug metabolizing enzymes   (CYP2E1, CYP2A6, CYP3A5, CYP2C9, CYP2C19,   CYP2D6, thiopurine methyl transferase and uridine diphosphate-glucoronyl transferases) as well as drug transporters (multidrug resistance 1 and organic cation transporters 1) were significantly different between South
Indians and other population groups. [18] [19] [20] [21] [22] [23] These findings raise the possibility that the frequency of variants of other genes including the OA dose determining VKORC1and CYP4F2 genes may be different in our population. This is the first study to establish the haplotype structure of the VKORC1 and genotype/allele frequencies of the CYP4F2 in India, in particular for South Indians. In this study, we have also compared our data with those of other population groups included in the HapMap project (http:// hapmap.ncbi.nlm.nih.gov/).
Materials and Methods

Study subjects
The present study included 470 unrelated healthy pattern and haplotype frequencies were estimated using HAPLOVIEW 4.1 [24] (Daly Lab, Broad Institute, Cambridge, MA02141, USA). All SNPs with minor allele frequencies of 0.01% were excluded and minimum haplotype frequency was set as 1%. Haplotype blocks were defined by using Table 3 ].
Results
Among
The Haplotype structure and LD pattern of VKORC1
in South Indian was compared with the HapMap population [ Figure 1 ].
In South Indian population, a strong LD pattern (D' >0. 8) was observed between all the SNPs except the LD pattern between rs8050894 and rs9934438 only moderate LD (D' <0.8) was observed. In Africans (YRI), a very strong LD pattern (D' =1) was observed between rs7294 and rs2359612, rs2359612 and rs9934438, rs2359612 and rs9923231, rs7294 and rs9923231 rs9934438 and rs9923231, rs7294 and rs9934438. Only low LD (D' <0. 5) was observed between rs2359612 and rs8050894. In Caucasians, all the SNPs were in strong LD (D' >0.8 HapMap populations were compared [ Figure 2 ].
Discussion
The frequencies of genetic variations may vary between populations as highlighted by several reports from different populations and from the HapMap projects. [25, 26] Hence, it is useful to have the population distribution profile of the genetic polymorphisms and LD pattern in the study population prior to genetic association studies. The present study is the first to report the genotype, allele and haplotype distribution and LD pattern of VKORC1 and CYP4F2 genes in South
Indian population with a large sample size. A significant difference in genotype, allele and Haplotype distribution was observed between the present study groups and other populations.
It is well-documented that the two alleles CYP2C9*2 (rs1799852) and CYP2C9*3 (rs1057910) were significantly associated with decreased warfarin dose requirements (warfarin sensitivity) and higher susceptibility to overdose. [27] A direct association of CYP2C9 genotype and anticoagulation status and bleeding was first reported by Higashi et al. [28] Furthermore, the allele frequencies of CYP2C9*2 and CYP2C9*3 diverge considerably among different ethnic groups. [29, 30] In our previous study, we have established the genotype and allele frequency of CYP2C9*2 and CYP2C9*3 in South Indian population. [19] In the present study, we have focused on the VKORC1 and CYP4F2 genes. Apart from SNPs in CYP2C9 gene and SNPs in the VKORC1 has been also correlated with warfarin dose requirement. [12, 31] The rs9934438 and rs9923231 polymorphisms are most commonly studied and associated with a lower warfarin dose requirement. [32] [33] [34] Another common SNP, the 3730 G > A (rs7294), located in the 3' untranslated region of the gene, is associated with increased warfarin dose requirements (warfarin resistance). [12, 35] In our study, we found that the rs7294 variant was highly frequent (80.1%).
Rieder et al. [12] conducted the haplotype analysis 
VKORC1 reference sequence [GenBank accession
number AY587020]) were used to construct the five major haplotypes and the association of these haplotypes were observed in Caucasian patients. A low dose haplotype group A and high dose haplotype group B were identified.
These haplotype frequencies also vary among the different ethnic populations. Haplotype A is more frequent in Asians (89%); whereas in Caucasians, haplotype B is more frequent (58%). [12] The previous pharmacogenetics studies have provided the indications that the South Indian population may have distinct polymorphic distribution features regarding the VKORC1 locus. In our study, we did not observe a significant difference in the genotyping frequencies of H7 haplotype group is associated with the higher dose requirement. [36] Our study on South Indians is in line with this observation.
In addition to the CYP2C9 and VKORC1 polymorphisms, a SNP in the CYP4F2 gene has been shown to contribute to warfarin dose requirement, albeit to a lesser extent, through genome wide association studies. [14] Another study has shown that patients with a variant allele namely CYP4F2*3, require higher maintenance warfarin dose as compared with those with wild type allele in Han Chinese patients. [33] In this study, we have established the maintenance dose and initial dose of OAs using the multivariate statistical techniques. [11, [37] [38] [39] [40] [41] [42] [43] [44] However, the proposed algorithms appear to be specific for each population group very likely due to differences in distribution of polymorphisms.
Thus, it is useful to establish the polymorphic profile of the study population/cohort before conducting pharmacogenetic studies on OAs. At this end, we have established the genotype, allele and haplotype frequencies of VKORC1 and CYP4F2 genotype and allele frequencies for the South Indian population.
Conclusion
The frequencies of the VKORC1 and CYP4F2 allele/ genotype in the South Indian population were distinct from other world population groups. These results will not only contribute to the better understanding of the genetic basis of ethnic variation in OA dose requirement response, but also establishes the frame work for future algorithm based dose determination of OAs in Indians.
